Abstract
Several new classes of antiviral drugs are undergoing development and should change the way that hepatitis C virus infection is treated in the future. It is likely that combinations of drugs that target different points in the viral replication and disease processes will prove most successful. It is hoped that such combinations will improve the efficacy, tolerability, and duration of antiviral treatment for this disease.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Viral / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Enzyme Inhibitors / therapeutic use*
-
Hepacivirus / physiology*
-
Hepatitis C, Chronic / therapy*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Oligopeptides / pharmacology
-
Oligopeptides / therapeutic use
-
Pentanoic Acids / pharmacology
-
Pentanoic Acids / therapeutic use
-
Pyrimidine Nucleosides / pharmacology
-
Pyrimidine Nucleosides / therapeutic use
Substances
-
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
-
Antibodies, Viral
-
Antiviral Agents
-
Enzyme Inhibitors
-
Immunologic Factors
-
Oligopeptides
-
Pentanoic Acids
-
Pyrimidine Nucleosides
-
telaprevir
-
valopicitabine